Deutsche Bank maintains Buy rating on Spyre Therapeutics, raises target price to $135

Overview

This report is Deutsche Bank's company research update on Spyre Therapeutics. The key change is the first-time inclusion of the third IBD combination SPY130 (α4β7 + IL-23) in risk-adjusted DCF valuation ahead of IL-23 data, and the target price is raised to $135. The report argues that the antibody strategy incubated by Paragon / supported by Fairmount is beginning to gain investor recognition in inflammation and immunology indications, and the market narrative is shifting from 'me-too' assets toward differentiated products that can be used for large pharma lifecycle management and pipeline expansion.

Core views

The report maintains a constructive view on SYRE and believes it should be valued line by line from the perspective of a strategic buyer: the three IBD combination therapies SPY120, SPY130, and SPY230 can each contribute value, while the non-IBD SPY072 rheumatology asset also provides additional optionality. Although SYRE's share price has already risen meaningfully recently, the report still believes that if each combination therapy has multiple blockbuster potential, a mid- to high-tens-of-billions-dollar acquisition by a large pharma company to strengthen its immunology and inflammation business is reasonable.

Analysis framework

The report uses a risk-adjusted DCF method, forecasting cash flows through 2040 and estimating the risk-adjusted peak sales, probability of success, and per-share valuation impact for the UC/CD combination therapies by program. The change in target price mainly comes from the approximately $24 per share positive contribution from adding SPY130, about $1 per share positive contribution from rolling the model to 22 Jun 26, and about $5 per share negative contribution from higher out-year R&D expense.

Methodology notes

• Valuation methodsRisk-adjusted DCF

  Risk-adjust future cash flows by pipeline and indication

  The target price is based on a risk-adjusted discounted cash flow valuation, with cash flows forecast through 2040, using a 15% WACC and a 0% terminal growth rate to reflect the R&D, regulatory, and commercialization risks of a small- and mid-cap biotechnology company.

• Clinical developmentPOS probability adjustment

  Assign success probabilities separately for UC and CD indications

  The report keeps the POS assumptions for SPY120, SPY130, and SPY230 at 70% for UC and 60% for CD, and calculates risk-adjusted peak sales accordingly.

• Product strategyCombination therapy lifecycle management

  Extend existing large-pharma franchises through differentiated antibody combinations

  The report believes IBD combination therapies do not only compete with monotherapies, but may also become strategic assets for large pharma companies in inflammation and immunology business development and lifecycle management.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• SYRE.US

  Primary covered stock

  Strengths

  Owns the three IBD combination therapies SPY120, SPY130, and SPY230, as well as the SPY072 rheumatology asset; valuation is supported by the inclusion of SPY130 and potential strategic acquisition logic.

  Weaknesses

  The company is still in clinical development, and revenue visibility depends on eventual pipeline success; parallel development across multiple programs increases R&D expense.

  Comparison

  The report notes that SYRE, along with ORKA and JADE, belongs to Paragon-incubated / Fairmount-supported companies, and recently rose in tandem with the news that APGE was acquired by ABBV for $10.9B, outperforming XBI.

  Risks

  Clinical trial failure, regulatory approval delays, deteriorating competitive dynamics, commercialization reimbursement pressure, and financing dilution.

• SPY130 (α4β7 + IL-23)

  New valuation contribution pipeline

  Strengths

  Included in the DCF model for the first time, with risk-adjusted peak sales of $1.09B for UC/CD combined, and is the main driver of the target price increase.

  Weaknesses

  Value depends on IL-23-related data and subsequent clinical validation of the combination therapy, and clinical uncertainty remains at present.

  Comparison

  Along with SPY120 and SPY230, it forms the three IBD combination therapies; the report believes that even if there is ultimately one best efficacy combination, the others may still be competitive relative to existing monotherapies.

  Risks

  SPY003 data do not support the IL-23 pathway hypothesis, the combination therapy's efficacy or safety falls short of expectations, or development is delayed.

• SPY230 (IL-23 + TL1A)

  Core IBD combination therapy

  Strengths

  The report maintains unadjusted peak sales of $9.57B and risk-adjusted peak sales of $4.14B for UC/CD combined, making it the largest single combination contribution in the valuation.

  Weaknesses

  The high peak-sales assumption requires strong clinical success, market penetration, and competitive advantage.

  Comparison

  Relative to SPY120 and SPY130, SPY230 has higher unadjusted and risk-adjusted peak sales in the report's model.

  Risks

  Competition from similar mechanisms or existing IBD therapies, clinical failure, and regulatory and reimbursement uncertainty.

• SPY120 (α4β7 + TL1A)

  Existing IBD combination therapy

  Strengths

  The report maintains unadjusted peak sales of $2.53B and risk-adjusted peak sales of $1.09B for UC/CD combined.

  Weaknesses

  Valuation assumptions were not raised, and the main value still needs to be validated by subsequent clinical data.

  Comparison

  It has the same unadjusted peak sales and risk-adjusted peak sales assumptions as the newly added SPY130 in the report.

  Risks

  Clinical, regulatory, competitive, and commercialization execution risks.

• SPY072 (TL1A)

  Non-IBD optional upside asset

  Strengths

  Targets rheumatology indications such as RA, PsA, and axSpA, providing strategic buyers with additional optionality beyond IBD.

  Weaknesses

  The report says its contribution to valuation is relatively modest, and the current core investment thesis remains focused on the IBD combination therapies.

  Comparison

  Compared with the three IBD combination therapies, SPY072 is more of an incremental upside source rather than the main target-price driver.

  Risks

  Indication development failure, competitive pressure, regulatory approval, or commercialization uncertainty.

Key data

• RatingBuyDeutsche Bank maintains a Buy rating.
• Target price135.00 USDPrior target price was 115.00 USD, raised by 20.00 USD, an increase of about 17%.
• Current price100.32 USDPrice as of 22 Jun 26.
• Implied upsideabout 34.6%Estimated using the $135.00 target price and the $100.32 current price.
• 2040 risk-adjusted peak sales6.32B USDUC/CD combined, raised from the previous 5.23B USD.
• SPY120 risk-adjusted peak sales1.09B USDUC/CD combined, unadjusted peak sales of 2.53B USD, UC POS 70%, CD POS 60%.
• SPY130 risk-adjusted peak sales1.09B USDIncluded in valuation for the first time, UC/CD combined, unadjusted peak sales of 2.53B USD.
• SPY230 risk-adjusted peak sales4.14B USDUC/CD combined, unadjusted peak sales of 9.57B USD.
• DCF discount rateWACC 15%Assumes a risk-free rate of 4.0%, an equity risk premium of 8.7%, and beta of 1.5.

Impact & implications

This report reinforces the investment narrative for SYRE as an inflammation and immunology combination-therapy platform asset. If upcoming SPY003 (IL-23) data support the combination-therapy hypothesis, the market may further increase pricing for the peak sales, success probabilities, and potential strategic acquisition value of the three IBD combinations; conversely, if the data or subsequent clinical progress falls short of expectations, the current valuation's sensitivity to pipeline success and parallel development will also amplify downside risk.

Risks

• Ongoing or planned clinical programs such as SPY001, SPY002, SPY003, SPY120, SPY130, SPY230, and SPY072 may fail.
• Any key program may be materially delayed or fail to obtain regulatory approval.
• Even if products are approved, they may lose competitive advantages during commercialization or fail to secure favorable reimbursement.
• Approved products and pipeline therapies may create competitive pressure.
• Future financing to support company operations and development plans may dilute existing shareholders.
• Parallel development of multiple IBD combination therapies will increase out-year R&D expense and create a negative impact on DCF valuation.

What to watch

• SPY003 (IL-23) monotherapy open-label data expected in 3Q26.
• After SPY130 is included in valuation, subsequent clinical initiation, trial design, and combination-therapy data validation.
• Efficacy, safety, and differentiation evidence for SPY120 and SPY230 in UC/CD.
• M&A and business development activity by large pharma in inflammation and immunology, especially the impact of ABBV's acquisition of APGE on comparable asset valuations.
• R&D spending pace, financing needs, and potential equity dilution.
• Competitive landscape, regulatory approvals, and reimbursement environment in IBD and rheumatology.